People · Operator
Named in public records as an officer, director or promoter · active 2018–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NanoView Biosciences, Inc. | — | Biotechnology | Series A | $17.5M | $41.3M | 2018 |
| Everest Biolabs, Inc. | — | Biotechnology | Series A | $4.3M | $10.3M | 2026 |
David Freedman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Freedman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| George Daaboul | 2 | 2 |
| Paul Meister | 1 | 12 |
| Michael Rubin | 1 | 8 |
| Ian Ratcliffe | 1 | 6 |
| David Walt | 1 | 6 |
| Andrea Jackson | 1 | 6 |
| VINIT NIJHAWAN | 1 | 3 |
| Parker Cassidy | 1 | 2 |
| GERALD WILLIAMSON | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.